Clinical Trials Logo

Precancerous Condition clinical trials

View clinical trials related to Precancerous Condition.

Filter by:

NCT ID: NCT00061997 Completed - Lung Cancer Clinical Trials

Inositol in Preventing Lung Cancer in Patients With Bronchial Epithelial Dysplasia Who Are Current or Former Smokers

Start date: May 2003
Phase: Phase 1
Study type: Interventional

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Inositol may be effective in preventing the development of lung cancer in patients with bronchial epithelial dysplasia. PURPOSE: This phase I trial is studying the side effects and best dose of inositol in preventing lung cancer in current or former smokers with bronchial epithelial dysplasia.

NCT ID: NCT00060099 Active, not recruiting - Clinical trials for Precancerous Condition

SGN-00101 in Treating Patients With Cervical Intraepithelial Neoplasia

Start date: May 2003
Phase: Phase 2
Study type: Interventional

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of or treat early cancer. SGN-00101 may be effective in preventing the development of cervical cancer in patients with cervical intraepithelial neoplasia. PURPOSE: This randomized phase II trial is studying how well SGN-00101 works in preventing cervical cancer in patients with cervical intraepithelial neoplasia and human papillomavirus.

NCT ID: NCT00060008 Terminated - Clinical trials for Precancerous Condition

Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma

Start date: April 2002
Phase: N/A
Study type: Interventional

RATIONALE: New imaging procedures such as fludeoxyglucose F 18 positron emission tomography (FDG-PET) and magnetic resonance (MR) perfusion imaging may improve the ability to detect disease progression, help doctors predict a patient's response to treatment, and help plan the most effective treatment. PURPOSE: This diagnostic trial is studying how well FDG-PET and MR perfusion imaging work in finding disease progression and determining response to treatment in patients with neurofibromatosis 1 and plexiform neurofibroma.

NCT ID: NCT00058331 Completed - Lymphoma Clinical Trials

Epoetin Alfa in Treating Anemia in Patients With Solid Tumors

Start date: June 2003
Phase: Phase 3
Study type: Interventional

RATIONALE: Epoetin alfa may stimulate red blood cell production and treat anemia in patients with solid tumors. It is not yet known whether epoetin alfa given once a week is more effective than epoetin alfa given once every 3 weeks in treating anemia. PURPOSE: Randomized phase III trial to study the effectiveness of epoetin alfa in treating anemia in patients who have solid tumors.

NCT ID: NCT00053937 Completed - Clinical trials for Precancerous Condition

Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas

Start date: December 2002
Phase: Phase 1
Study type: Interventional

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Pirfenidone may slow the growth or prevent further development of plexiform neurofibromas. PURPOSE: Phase I trial to study the effectiveness of pirfenidone in treating young patients who have neurofibromatosis type 1 and plexiform neurofibroma.

NCT ID: NCT00042900 Completed - Lymphoma Clinical Trials

Pyroxamide in Treating Patients With Advanced Cancer

Start date: April 2002
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of pyroxamide in treating patients who have advanced cancer.

NCT ID: NCT00031759 Completed - Cervical Cancer Clinical Trials

Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia

Start date: June 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Chemoprevention therapy is the use of certain substances to try to prevent the development of cancer. Applying topical imiquimod before abnormal cervical cells are removed may be effective in preventing cervical cancer. PURPOSE: Randomized phase II trial to study the effectiveness of applying topical imiquimod before abnormal cervical cells are removed in preventing cervical cancer in patients who have recurrent or persistent cervical neoplasia.

NCT ID: NCT00030264 Completed - Clinical trials for Precancerous Condition

Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas

Start date: February 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining methotrexate with vinblastine may be effective treatment for neurofibromatosis type 1 associated with progressive plexiform neurofibromas. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have neurofibromatosis type 1 associated with progressive plexiform neurofibromas.

NCT ID: NCT00027976 Withdrawn - Clinical trials for Precancerous Condition

Celecoxib in Preventing Skin Cancer in Patients With Actinic Keratoses

Start date: December 2001
Phase: Phase 2/Phase 3
Study type: Interventional

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of celecoxib may be an effective way to prevent actinic keratoses. PURPOSE: Randomized phase II/III trial to determine the effectiveness of celecoxib in preventing skin cancer in patients who have actinic keratoses.

NCT ID: NCT00006466 Active, not recruiting - Clinical trials for Multiple Myeloma and Plasma Cell Neoplasm

Beta Alethine in Treating Patients With Myeloma

Start date: August 2000
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Biological therapies such as beta alethine use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I/II trial to study the effectiveness of beta alethine in treating patients who have myeloma.